11 research outputs found
Π‘ΠΏΠΎΡΠΎΠ± ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡ ΡΠΎΠ»ΠΈ ΠΎΠ»ΠΈΠ³ΠΎΠ³Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠΈΠ»Π΅Π½Π³ΡΠ°Π½ΠΈΠ΄ΠΈΠ½Π° Π²ΡΡΠΎΠΊΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΠΈΡΡΠΎΡΡ
Objectives. Given that microorganisms can become resistant to certain groups of drugs and considering also their ability to form biofilms, the development of new drugs that are active against adapted microflora is required. This study focused on the development of a new method for the synthesis of a promising compound, the branched hydrosuccinate oligohexamethylene guanidine (OHMGsucc), with high purity that meets the standards of the 14th edition State Pharmacopeia of the Russian Federation (SPRF). Previously proposed methods have managed to isolate this product, which, however, complies with the requirements of the outdated SPRF. Therefore, the main aim of this study was to update the regulatory framework for the indicated OHMG salt for its further use in the pharmaceutical industry according to modern standards.Methods. To control the residual impurities of hexamethylenediamine (HMDA) and guanidine hydrochloride (GHC), high-performance liquid chromatography (HPLC) was applied using a Thermo Scientific Dionex UltiMate 3000 chromatograph, and the chromatographic signals of the test solution with those of a standard sample solution obtained by a previously published conventional method were compared.Results. The HPLC experimental data indicated a significant difference in the quantitative content of HMDA and GHC observed for the new and older preparation method of the branched OHMGsucc, suggesting that the method disclosed in this article can be used to obtain highly pure OHMGsucc.Conclusions. The specified compound was standardized with the parameter βrelated impuritiesβ according to the current (14th) edition of the SPRF. The effectiveness and reproducibility of the proposed method was experimentally confirmed. In addition, a process diagram for the preparation of the indicated OHMG salt was prepared.Π¦Π΅Π»ΠΈ. ΠΠ° ΡΠΎΠ½Π΅ ΠΏΡΠΈΠΎΠ±ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΌΠΈΠΊΡΠΎΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌΠ°ΠΌΠΈ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ ΠΊ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π½ΡΠΌ Π³ΡΡΠΏΠΏΠ°ΠΌ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΡΡΠ΅Π΄ΡΡΠ², Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΠ΅ΠΉ ΠΎΠ±ΡΠ°Π·ΠΎΠ²ΡΠ²Π°ΡΡ Π±ΠΈΠΎΠΏΠ»Π΅Π½ΠΊΠΈ, ΡΡΠ΅Π±ΡΡΡΡΡ Π½ΠΎΠ²ΡΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ, Π°ΠΊΡΠΈΠ²Π½ΡΠ΅ ΠΏΡΠΎΡΠΈΠ² Π°Π΄Π°ΠΏΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΌΠΈΠΊΡΠΎΡΠ»ΠΎΡΡ. CΡΠ°ΡΡΡ ΠΏΠΎΡΠ²ΡΡΠ΅Π½Π° ΠΈΠ·ΡΡΠΊΠ°Π½ΠΈΡ ΡΠΏΠΎΡΠΎΠ±Π° ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΡ β ΡΠ°Π·Π²Π΅ΡΠ²Π»Π΅Π½Π½ΠΎΠ³ΠΎ Π³ΠΈΠ΄ΡΠΎΡΡΠΊΡΠΈΠ½Π°ΡΠ° ΠΎΠ»ΠΈΠ³ΠΎΠ³Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠΈΠ»Π΅Π½Π³ΡΠ°Π½ΠΈΠ΄ΠΈΠ½Π° Ρ Π²ΡΡΠΎΠΊΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΡΡ ΡΠΈΡΡΠΎΡΡ, ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠ΅ΠΉ Π½ΠΎΡΠΌΠ°ΠΌ ΠΠΎΡΡΠ΄Π°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ Π€Π°ΡΠΌΠ°ΠΊΠΎΠΏΠ΅ΠΈ 14 ΠΈΠ·Π΄Π°Π½ΠΈΡ. Π’Π°ΠΊ ΠΊΠ°ΠΊ ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½Π½ΡΠ΅ ΡΠ°Π½Π΅Π΅ ΠΌΠ΅ΡΠΎΠ΄Ρ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ»ΠΈ ΠΏΠΎΠ»ΡΡΠΈΡΡ ΠΏΡΠΎΠ΄ΡΠΊΡ, ΡΠ΄ΠΎΠ²Π»Π΅ΡΠ²ΠΎΡΡΡΡΠΈΠΉ ΡΡΠ΅Π±ΠΎΠ²Π°Π½ΠΈΡΠΌ ΡΡΡΠ°ΡΠ΅Π²ΡΠ΅ΠΉ ΠΠΎΡΡΠ΄Π°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ Π€Π°ΡΠΌΠ°ΠΊΠΎΠΏΠ΅ΠΈ, ΡΠΎ ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠΉ ΡΠ΅Π»ΡΡ ΡΠ²Π»ΡΠ»Π°ΡΡ Π°ΠΊΡΡΠ°Π»ΠΈΠ·Π°ΡΠΈΡ Π½ΠΎΡΠΌΠ°ΡΠΈΠ²Π½ΠΎΠΉ Π±Π°Π·Ρ Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΡΠΊΠ°Π·Π°Π½Π½ΠΎΠΉ ΡΠΎΠ»ΠΈ ΠΎΠ»ΠΈΠ³ΠΎΠ³Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠΈΠ»Π΅Π½Π³ΡΠ°Π½ΠΈΠ΄ΠΈΠ½Π° Π΄Π»Ρ Π΅Π΅ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅Π³ΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π² ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΡΡΠ°ΡΠ»ΠΈ ΡΠΎΠ³Π»Π°ΡΠ½ΠΎ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠΌ ΡΡΠ°Π½Π΄Π°ΡΡΠ°ΠΌ.ΠΠ΅ΡΠΎΠ΄Ρ. ΠΠ»Ρ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ ΠΏΡΠΈΠΌΠ΅ΡΠ½ΡΡ
ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ β Π³Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠΈΠ»Π΅Π½Π΄ΠΈΠ°ΠΌΠΈΠ½Π° ΠΈ Π³ΡΠ°Π½ΠΈΠ΄ΠΈΠ½Π° Π³ΠΈΠ΄ΡΠΎΡ
Π»ΠΎΡΠΈΠ΄Π° ΠΏΡΠΈΠΌΠ΅Π½ΡΠ»ΠΈ Π²ΡΡΠΎΠΊΠΎΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΡ ΠΆΠΈΠ΄ΠΊΠΎΡΡΠ½ΡΡ Ρ
ΡΠΎΠΌΠ°ΡΠΎΠ³ΡΠ°ΡΠΈΡ, ΠΊΠΎΡΠΎΡΡΡ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Π½Π° Ρ
ΡΠΎΠΌΠ°ΡΠΎΠ³ΡΠ°ΡΠ΅ Thermo Scientific Dionex UltiMate 3000 ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ Π²Π½Π΅ΡΠ½Π΅Π³ΠΎ ΡΡΠ°Π½Π΄Π°ΡΡΠ°.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΡΡ
Π΄Π°Π½Π½ΡΡ
, ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ
Ρ ΠΏΠΎΠΌΠΎΡΡΡ Π²ΡΡΠΎΠΊΠΎΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΠΆΠΈΠ΄ΠΊΠΎΡΡΠ½ΠΎΠΉ Ρ
ΡΠΎΠΌΠ°ΡΠΎΠ³ΡΠ°ΡΠΈΠΈ, ΠΎΡΠΎΠ±ΡΠ°ΠΆΠ΅Π½Π° ΡΠ°Π·Π½ΠΈΡΠ° Π² ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΌ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠΈ ΠΎΡΡΠ°ΡΠΎΡΠ½ΡΡ
ΠΏΡΠΈΠΌΠ΅ΡΠ΅ΠΉ Π² ΡΠΎΡΡΠ°Π²Π΅ ΡΡΠ±ΡΡΠ°Π½ΡΠΈΠΈ ΡΠ°Π·Π²Π΅ΡΠ²Π»Π΅Π½Π½ΠΎΠ³ΠΎ Π³ΠΈΠ΄ΡΠΎΡΡΠΊΡΠΈΠ½Π°ΡΠ° ΠΎΠ»ΠΈΠ³ΠΎΠ³Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠΈΠ»Π΅Π½Π³ΡΠ°Π½ΠΈΠ΄ΠΈΠ½Π°, ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΠΎΠΉ Π΄Π²ΡΠΌΡ ΡΠ°Π·Π½ΡΠΌΠΈ ΡΠΏΠΎΡΠΎΠ±Π°ΠΌΠΈ. ΠΡΠΌΠ΅ΡΠ΅Π½ΠΎ, ΡΡΠΎ ΡΠΏΠΎΡΠΎΠ±, ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½Π½ΡΠΉ Π°Π²ΡΠΎΡΠ°ΠΌΠΈ Π½Π°ΡΡΠΎΡΡΠ΅ΠΉ ΡΡΠ°ΡΡΠΈ, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΡΠ½ΠΈΠ·ΠΈΡΡ ΠΈΡ
ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΊΠΎΠ½Π²Π΅Π½ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ.ΠΡΠ²ΠΎΠ΄Ρ. Π‘ΠΎΠ³Π»Π°ΡΠ½ΠΎ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π½ΡΠΌ Π΄Π°Π½Π½ΡΠΌ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π° ΡΡΠ°Π½Π΄Π°ΡΡΠΈΠ·Π°ΡΠΈΡ ΡΠΊΠ°Π·Π°Π½Π½ΠΎΠ³ΠΎ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΡ ΠΏΠΎ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΡ Β«Π ΠΎΠ΄ΡΡΠ²Π΅Π½Π½ΡΠ΅ ΠΏΡΠΈΠΌΠ΅ΡΠΈΒ» Π² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΈΠΈ Ρ Π°ΠΊΡΡΠ°Π»ΡΠ½ΡΠΌ Π½Π° Π΄Π°Π½Π½ΡΠΉ ΠΌΠΎΠΌΠ΅Π½Ρ ΠΈΠ·Π΄Π°Π½ΠΈΠ΅ΠΌ ΠΠΎΡΡΠ΄Π°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ Π€Π°ΡΠΌΠ°ΠΊΠΎΠΏΠ΅ΠΈ. ΠΡΠ»Π΅Π΄ΡΡΠ²ΠΈΠ΅ ΡΠΎΠ³ΠΎ, ΡΡΠΎ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½Π½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠΎΠ΄Π° ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΠΎ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠ΄ΠΈΠ»Π°ΡΡ, Π½Π° Π·Π°ΠΊΠ»ΡΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠΌ ΡΡΠ°ΠΏΠ΅ ΡΠ°Π±ΠΎΡΡ Π±ΡΠ»Π° ΡΠΎΡΡΠ°Π²Π»Π΅Π½Π° ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΡ
Π΅ΠΌΠ° ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡ ΡΠΊΠ°Π·Π°Π½Π½ΠΎΠΉ ΡΠΎΠ»ΠΈ ΠΎΠ»ΠΈΠ³ΠΎΠ³Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠΈΠ»Π΅Π½Π³ΡΠ°Π½ΠΈΠ΄ΠΈΠ½Π°
Π Π°Π·ΡΠ°Π±ΠΎΡΠΊΠ° ΠΈ Π²Π°Π»ΠΈΠ΄Π°ΡΠΈΡ ΠΌΠ΅ΡΠΎΠ΄Π° ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ ΠΌΠΎΠ½ΠΎΠΌΠ΅ΡΠ½ΠΎΠΉ ΠΏΡΠΈΠΌΠ΅ΡΠΈ Π³ΠΈΠ΄ΡΠΎΡ Π»ΠΎΡΠΈΠ΄Π° Π³ΡΠ°Π½ΠΈΠ΄ΠΈΠ½Π° Π² ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠ±ΡΡΠ°Π½ΡΠΈΠΈ Β«ΡΠ°Π·Π²Π΅ΡΠ²Π»Π΅Π½Π½ΡΠΉ Π³ΠΈΠ΄ΡΠΎΡ Π»ΠΎΡΠΈΠ΄ ΠΎΠ»ΠΈΠ³ΠΎΠ³Π΅ΠΊΡΠ°ΠΌΠ΅ΡΠΈΠ»Π΅Π½Π³ΡΠ°Π½ΠΈΠ΄ΠΈΠ½Π°Β»
Some existing methodologies for quantitative estimation of guanidine hydrochloride during the analysis of various samples were described. Their shortcomings impeding the implementation of the control of the monomer in the pharmaceutical substance were identified. A method for quantitative determination of guanidine hydrochloride in pharmaceutical substance βbranched oligo(hexamethyleneguanidine) hydrochlorideβ by high performance liquid chromatography was developed. The method was validated to standardize the substance by the parameter βimpurity compoundsβ.ΠΠΏΠΈΡΠ°Π½Ρ ΡΡΡΠ΅ΡΡΠ²ΡΡΡΠΈΠ΅ ΠΌΠ΅ΡΠΎΠ΄Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ Π³ΠΈΠ΄ΡΠΎΡ
Π»ΠΎΡΠΈΠ΄Π° Π³ΡΠ°Π½ΠΈΠ΄ΠΈΠ½Π° ΠΏΡΠΈ Π°Π½Π°Π»ΠΈΠ·Π΅ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΠΎΠ±ΡΠ°Π·ΡΠΎΠ², ΡΠΊΠ°Π·Π°Π½Ρ ΠΈΡ
Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΊΠΈ, ΠΏΡΠ΅ΠΏΡΡΡΡΠ²ΡΡΡΠΈΠ΅ ΠΎΡΡΡΠ΅ΡΡΠ²Π»Π΅Π½ΠΈΡ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ ΠΌΠΎΠ½ΠΎΠΌΠ΅ΡΠ° Π² ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠ±ΡΡΠ°Π½ΡΠΈΠΈ. Π Π°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π° ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠ° ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ Π³ΠΈΠ΄ΡΠΎ-Ρ
Π»ΠΎΡΠΈΠ΄Π° Π³ΡΠ°Π½ΠΈΠ΄ΠΈΠ½Π° Π² ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠ±ΡΡΠ°Π½ΡΠΈΠΈ Β«ΡΠ°Π·Π²Π΅ΡΠ²Π»Π΅Π½Π½ΡΠΉ Π³ΠΈΠ΄ΡΠΎΡ
Π»ΠΎΡΠΈΠ΄ ΠΎΠ»ΠΈΠ³ΠΎΠ³Π΅ΠΊΡΠ°-ΠΌΠ΅ΡΠΈΠ»Π΅Π½Π³ΡΠ°Π½ΠΈΠ΄ΠΈΠ½Π°Β» Ρ ΠΏΠΎΠΌΠΎΡΡΡ Π²ΡΡΠΎΠΊΠΎΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΠΆΠΈΠ΄ΠΊΠΎΡΡΠ½ΠΎΠΉ Ρ
ΡΠΎΠΌΠ°ΡΠΎΠ³ΡΠ°ΡΠΈΠΈ, ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π° Π΅Π΅ Π²Π°Π»ΠΈΠ΄Π°ΡΠΈΡ Ρ ΡΠ΅Π»ΡΡ ΡΡΠ°Π½Π΄Π°ΡΡΠΈΠ·Π°ΡΠΈΠΈ ΡΡΠ±ΡΡΠ°Π½ΡΠΈΠΈ ΠΏΠΎ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΡ Β«ΠΏΡΠΈΠΌΠ΅ΡΠ½ΡΠ΅ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΡΒ»
DOSAGE FORMS OF NONSTEROIDAL ANTI-INFLAMMATORY PHARMACEUTICAL SUBSTANCE FOR CONTROLLED RELEASE
This review is about nonsteroidal anti-inflammatory drugs and different approaches to development of pharmaceutical forms for controlled nonsteroidal anti-inflammatory drug release. Natural and synthetic biocompatible polymers used as drug carriers were considered. Different methods used for production of polymeric microparticles and formulations of nonsteroidal anti-inflammatory agents based on them were discussed. Characterization of microparticles with encapsulated nonsteroidal anti-inflammatory agents was given
An effective method for preparation of high purity oligohexamethylene guanidine salts
Objectives. Given that microorganisms can become resistant to certain groups of drugs and considering also their ability to form biofilms, the development of new drugs that are active against adapted microflora is required. This study focused on the development of a new method for the synthesis of a promising compound, the branched hydrosuccinate oligohexamethylene guanidine (OHMGsucc), with high purity that meets the standards of the 14th edition State Pharmacopeia of the Russian Federation (SPRF). Previously proposed methods have managed to isolate this product, which, however, complies with the requirements of the outdated SPRF. Therefore, the main aim of this study was to update the regulatory framework for the indicated OHMG salt for its further use in the pharmaceutical industry according to modern standards.Methods. To control the residual impurities of hexamethylenediamine (HMDA) and guanidine hydrochloride (GHC), high-performance liquid chromatography (HPLC) was applied using a Thermo Scientific Dionex UltiMate 3000 chromatograph, and the chromatographic signals of the test solution with those of a standard sample solution obtained by a previously published conventional method were compared.Results. The HPLC experimental data indicated a significant difference in the quantitative content of HMDA and GHC observed for the new and older preparation method of the branched OHMGsucc, suggesting that the method disclosed in this article can be used to obtain highly pure OHMGsucc.Conclusions. The specified compound was standardized with the parameter βrelated impuritiesβ according to the current (14th) edition of the SPRF. The effectiveness and reproducibility of the proposed method was experimentally confirmed. In addition, a process diagram for the preparation of the indicated OHMG salt was prepared
Development and validation of the method of control monomer impurities guanidine hydrochloride in pharmaceutical substance βbranched hydrochloride oligo(hexamethyleneguanidine)β
Some existing methodologies for quantitative estimation of guanidine hydrochloride during the analysis of various samples were described. Their shortcomings impeding the implementation of the control of the monomer in the pharmaceutical substance were identified. A method for quantitative determination of guanidine hydrochloride in pharmaceutical substance βbranched oligo(hexamethyleneguanidine) hydrochlorideβ by high performance liquid chromatography was developed. The method was validated to standardize the substance by the parameter βimpurity compoundsβ
Chemical Modification of Oligo(Hexamethylene Guanidine): Synthesis of Alkylated Derivatives and Their Estimated Activity Against Mycobacterium Smegmatis
Preparation and Activity of a Complex of Oligohexamethyleneguanine with P-Aminosalicylic Acid Derivatives
Oligohexamethylene Guanidine Derivative as a Means to Prevent Biological Fouling of a Polymer-Based Composite Optical Oxygen Sensor
The use of biocidal agents is a common practice for protection against biofouling in biomass-rich environments. In this paper, oligohexamethyleneguanidine (OHMG) polymer, known for its biocidal properties, was further modified with para-aminosalicylic acid (PAS) to enhance its properties against microorganisms coated with a lipid membrane. The structure of the product was confirmed by 1H NMR, 13C NMR, and FTIR spectroscopy. The values of the minimum inhibitory concentration (MIC) against Mycobacterium smegmatis ATCC 607 and Pseudomonas chlororaphis 449 were found to be 1.40 and 1.05 ΞΌg/mL, respectively. The synthesized substance was used as an additive to the polymer matrix of the composite optical oxygen sensor material. A series of samples with different contents of OHMG-PAS was prepared using a co-dissolution method implying the fabrication of a coating from a solution containing both polymers. It turned out that the mutual influence of the components significantly affects the distribution of the indicator in the matrix, surface morphology, and contact angle. The optimal polymer content turned out to be wt.3%, at which point the water contact angle reaches almost 122Β°, and the fouling rate decreases by almost five times, which is confirmed by both the respiratory MTT assay and confocal microscopy with staining. This opens up prospects for creating stable and biofouling-resistant sensor elements for use in air tanks or seawater